WELCOME TO ACTELION S AGM 2016

Transcription

1 WELCOME TO ACTELION S AGM 2016 Copyright

2 ACTELION S ANNUAL GENERAL MEETING 2016 MEETING STRUCTURE Opening Remarks Business Review 2015 Agenda & Proposals Jean-Pierre Garnier, Chairman of the Board Jean-Paul Clozel, Chief Executive Officer André Muller, Chief Financial Officer Jean-Pierre Garnier, Chairman of the Board Marian Borovsky, Secretary of the Board of Directors 2

3 FORMAL DECLARATIONS REGARDING THE CONSTITUTION OF THE MEETING 3

4 IHR epad / YOUR epad Ja Oui Yes Enthaltung Abstention Abstention Nein Non No 4

5 FORMAL DECLARATIONS REGARDING THE CONSTITUTION OF THE MEETING 5

6 OPENING REMARKS BY THE CHAIRMAN OF THE BOARD Jean-Pierre Garnier 6

7 2015 KEY FINANCIAL HIGHLIGHTS PRODUCT SALES >CHF 2 BILLION Core EPS CHF 6.16 CORE EARNINGS >CHF 800 MILLION CASH RETURNED TO SHAREHOLDERS ALMOST CHF 1 BILLION 7

8 ACTELION SHARE PRICE PERFORMANCE AGM 2015 Share price development 21% in 2015 ACTELION SWISS SMI Jan-15 Apr-15 Jul-15 Oct-15 Jan-16 Apr-16 8

9 DELIVERING ON OUR STRATEGY CREATES VALUE ALMOST CHF 1 BILLION RETURNED TO SHAREHOLDERS IN 2015 CASH RETURNED TO SHAREHOLDERS SHARE PRICE PERFORMANCE

10 OPENING REMARKS BY THE CHAIRMAN OF THE BOARD Jean-Pierre Garnier 10

11 OUTSTANDING SUCCESS IN 2015 Jean-Paul Clozel, CEO 11

12 A SUCCESSFUL YEAR FOR ACTELION Product success Opsumit launch and approval of Uptravi Pipeline success Pipeline progress Financial success Sales of over CHF 2 billion and substantial shareholder return 12

13 PAH TRANSFORMING OUR PAH PORTFOLIO 13

14 DIVERSE PORTFOLIO: KEY PROJECTS BEYOND PAH Cadazolid: Clostridium difficile associated diarrhea Ponesimod: Multiple sclerosis Clazosentan: Reversal of vasospasm post-asah Cenerimod: Systemic lupus erythematosus Other projects in early stage: Progressing well 14

15 ACTELION CLEAR VISION FOR FUTURE GROWTH We can create one of the most successful biotech companies in the world! 15

16 STRONG FINANCIAL PERFORMANCE IN 2015 André C. Muller, CFO 16

17 FY PRODUCT SALES 2,042 1, PERFORMANCE 11% ,784 Excluding prior year rebate reversals and at constant exchange rates 17

18 FY CORE R&D EXPENDITURE INVESTING IN FUTURE GROWTH

19 FY CORE EARNINGS PERFORMANCE 25% Excluding prior year rebate reversals and at constant exchange rates 19

20 FY CORE EARNINGS PER SHARE PERFORMANCE 26% Excluding prior year rebate reversals and at constant exchange rates 20

21 FY 2015 CASH POSITION AND CASH FLOW , Gross cash 31 Dec 14 Operating cash flow Cash returned to shareholders 1st line share purchase ESOP proceeds Bond repayment, other itmes Net cash 31 December 15 21

22 Q FINANCIAL OVERVIEW Variance Q Q CHF CER Product sales CHF million Core operating income CHF million Core diluted EPS CHF Operating income CHF million US GAAP diluted EPS CHF % 11% % 8% % 17% % 3% % 11% 22

23 2016 FINANCIAL GUIDANCE AT CONSTANT EXCHANGE RATES High single-digit percentage core operating income growth, at constant exchange rates and barring unforeseen events 23

24 CONCLUDING REMARKS BY THE CHAIRMAN OF THE BOARD 24